#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Segmentation-CAGR rate
Text
Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market size, Scope, Growth Opportunities, Trends by Manufacturers and Forecast to 2028
Industry Analysis
The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 5.25% in the above-mentioned forecast period. Rise in the prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) drives the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market.
Additionally, the credible Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market report helps the manufacturer in finding out the effectiveness of the existing channels of distribution, advertising programs, or media, selling methods and the best way of distributing the goods to the eventual consumers. Taking up such market research report is all the time beneficial for any company whether it is a small scale or large scale, for marketing of products or services. It makes effortless for healthcare industry to visualize what is already available in the market, what market anticipates, the competitive environment, and what should be done to surpass the competitor.
Get a Free Sample of The Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Market Insights and Scope
Acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics are the defined as the type of collection of drugs and therapeutic systems available in the market for its treatment. In this cancer, the blood and bone marrow are affected with cancerous cells which result in compromise of integrity of white blood cells. It is most common in pediatric patients as it occurs when the bone marrow cell consists of errors in its DNA, this generally occurs while the bone marrow is under development.
An international Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market research report examines competitive companies and manufacturers in the global market. Competitive analysis carried out in this market report puts forth the moves of the key players in the healthcare industry such as new product launches, expansions, agreements, joint ventures, partnerships, and recent acquisitions. This market report puts light on various aspects of marketing research that range from important industry trends, market size, market share estimates, sales volume, emerging trends, product consumption, customer preferences, historic data along with future forecast and key player analysis. It studies market by product type, applications and growth factors.
Get full access to the report: https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Industry Segmentation
The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented on the basis of age group, diagnosis, drug type, therapy, cell type and route of administration. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of age group, the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented into pediatrics and adults.
Based on diagnosis, the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented into biopsy & bone marrow aspiration, complete blood count (CBC) & differential, presence of philadelphia chromosome, spinal tap & cerebrospinal fluid (CSF) analysis, immunophenotyping/phenotyping by flow cytometry and polymerase chain reaction (PCR).
Based on drug type, the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented into existing drugs and pipeline drugs.
Based on therapy, the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented into targeted drugs & immunotherapy, chemotherapy, radiation therapy, stem cell transplantation and pipeline.
Based on cell type, the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is segmented into philadelphia chromosome, precursor B-cell ALL and T-cell all.
The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is also segmented on the basis of role of administration into oral and parenteral.
Market Country Level Analysis
The countries covered in the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market report is
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
An influential Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market research report displays an absolute outline of the market that considers various aspects such as product definition, customary vendor landscape, and market segmentation. Currently, businesses are relying on the diverse segments covered in the market research report to a great extent which gives them better insights to drive the business on the right track. The competitive analysis brings into light a clear insight about the market share analysis and actions of the key industry players. With this info, businesses can successfully make decisions about business strategies to accomplish maximum return on investment (ROI).
Industry Share Analysis
The major players covered in the acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market report is
Amgen Inc.; Bristol-Myers Squibb Company; Erytech Pharma; Novartis AG; Pfizer Inc.; Rare Disease Therapeutics, Inc.; Sanofi; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Genmab A/S; Baxter; Gilead Sciences, Inc.; CELGENE CORPORATION; Eisai Co., Ltd.; SymBio Pharmaceuticals Limited; Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.
Browse Related Reports@
Global Frozen Vegetables Market
South Africa Battery Market
Global Plant-Based Egg Market
Global Nutritional Beverages market
Spain Fuel Cards Market for Commercial Fleet
Europe Fall Detection System Market
About Us:Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Growing Popularity#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Global Leading Brands#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market drivers-advantages#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Segmentation-CAGR rate#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Demands-Size-Share-Top Trends#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Industry-Competitors#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Growth-Competition#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market 2028 by Types-Application#Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market healthcare Industry
0 notes
Text
T-cell Acute Lymphoblastic Leukemia Market Key Players, Industry Overview and Forecast 2018-2026
T-cell Acute Lymphoblastic Leukemia Market:Overview
Significant players operating in the global T-cell acute lymphoblastic leukemia market incorporate Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Sanofi, and Celgene Corporation. Increasing strategic collaborations, mergers and acquisitions, product launches, and flood in clinical trials are estimated to bolster the global market in the forthcoming years. For instance, Novartis AG, in in January 2017, consented to get into a tie-up with different players in the market to co-market and co-create oncology therapies.
As indicated in the recent report by Transparency Market Research, the global T-cell acute lymphoblastic leukemia market is prognosticated dwell on a decent CAGR of 8.4% within the forecast period from 2018 to 2026. In 2017, the T-cell acute lymphoblastic leukemia market was valued around worth US$ 330.5 mn.
Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=53283
The global T-cell acute lymphoblastic leukemia market can be segregated based on treatment into following segments - radiation therapy, chemotherapy, bone marrow transplant, immunotherapy, and targeted therapy. Among these, the segment of chemotherapy treatment held the majority of share of global T-cell acute lymphoblastic leukemia market in 2017 as far as revenue was concerned. The mentioned segment is estimated to rise at a notable CAGR in the span of upcoming years because of its huge product range, increased prescription rate, and simple availability.
North America dominated the global market and is projected to pick up market share before the finish of 2026. The market in North America is driven by increment in frequency of T-cell acute lymphoblastic leukemia, new product endorsements, strong product pipeline, and ascend in health care expenditure.
Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=53283
Better Government Policies and Initiatives to Contribute in Market Development
Betterment in the pharmaceutical sector, government initiatives, rising healthcare expenditure, flood in research and development, and surging number of in patient pool are estimated to unfurl the global market within the forecast period from 2018 to 2026.
T-cell acute lymphoblastic leukemia can be categorized as kind of acute lymphoblastic leukemia that has lymphoma like symptoms. It for the most part affects white platelets called T lymphocytes. T-cell acute lymphoblastic leukemia is progressively common in children above the age of 5 years. T-cell acute lymphoblastic leukemia holds around 15% to 20% of all acute lymphoblastic leukemia. As indicated by the American Society of Clinical Oncology (ASCO), about 5,970 instances of acute lymphoblastic leukemia (ALL) were diagnosed in 2017 in the US.
Increased Clinical Trials to Pump up Market Demand
Demand with respect to therapeutics for T-cell acute lymphoblastic leukemia has grown by leaps and bounds in the past couple of years. This resulted in increase in clinical trials in early and late stages of medication development. A recent example is, Baylor College of Medicine in 2017, began first stage clinical trials of 28zeta CAR T cells/CD5.CAR, Cytoxan for T-cell acute lymphoblastic leukemia. The trial is foreseen to get completed by 2036, June.
Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=53283
Surging advancement in technology and R&D activities related to manufacturing procedures are projected to auger the productivity of pharmaceutical development. Nonetheless, mind-boggling expense associated with the treatment of T-cell acute lymphoblastic leukemia is anticipated to restrain the market in the forthcoming years. Development of therapeutics require the utilization of costly instrumentation that as well expands the general cost of therapeutics and treatment for the ailment. For instance, the cost of chemotherapeutic Nelarabine is in the range of US$75,000 and US$ 100,000 in the United States.
The study presented here is based on a report by Transparency Market Research (TMR) titled “T-cell Acute Lymphoblastic Leukemia Market (Treatment - Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, Immunotherapy; End user - Hospital, Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026.”
More Trending Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/spectrometry-market-to-cross-the-value-of-us-13-8-bn-by-the-end-of-2028--says-tmr-study-301523017.html
https://www.prnewswire.com/news-releases/skin-care-devices-market-to-advance-at-cagr-of-9-9-during-20212028--says-tmr-301510121.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com
0 notes
Text
Leukemia Therapeutics Market By Therapy Analysis, Trends – Global Forecast by 2020 - 2025
Uncontrolled growth of cells is caused due to mutation to genes in cancer. The uncontrolled grown cell again moves from one part of body to another through blood and lymph system. There are different types of cancer out of which Leukemia is one. Cancer which is formed in blood tissues is called as Leukemia. Leukemia occurs due to the uncontrolled growth of with blood cells in the bone marrow. White blood cells are the protectors of our body from different infections. Leukemia is the most common type of cancer that is caused among adult males because they are not diagnosed at proper time. The most familiar syndrome of Leukemia is weight loss, night sweats, fever, frequent infections and enlarged liver size. There are different types of Leukemia out of which are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.
How Big is the Global Leukemia Therapeutics Market?
The Global Leukemia Therapeutic Market is expected to be around US$ 13 Billion by 2025 at a CAGR of 4% in the given forecast period.
The major driving factors of Global Leukemia Therapeutic Market are as follows:
Novel developments for drug discovery approaches
Increase incidence number of target disease
Increase aging population
Not much competition in the market
The restraining factors of Global Leukemia Therapeutic Market are as follows:
Expensive treatment
Adverse effect of the treatment
Read more information about Global Market with Impact of Covid-19
To get Sample Copy of Business Report through this link: https://www.sdki.jp/sample-request-105927
The Global Leukemia Therapeutic Market is segmented on the lines of its therapy, type and regional. Based on therapy segmentation it covers Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy, other. Based on type segmentation it covers Chronic leukemia, acute leukemia, others. The Global Leukemia Therapeutic Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
An overview of the global market for Global Leukemia Therapeutic Market and related technologies.
Analyses of global market trends, with data from 2016, estimates for 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2025.
Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.
Discussion of research and development, and the demand for new products and new applications.
Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Leukemia Therapeutic Market has been segmented as below:
By Therapy Analysis:
Chemotherapy
Biological Therapy
Radiation therapy
Targeted therapy
Other
By Type Analysis:
Chronic leukemia
Chronic lymphatic leukemia
Chronic myeloid leukemia
Acute leukemia
Acute lymphatic leukemia
Acute myeloid leukemia
Others
By Regional Analysis:
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
Obtain the most up to date information available on all Global Leukemia Therapeutic Market.
Identify growth segments and opportunities in the industry.
Facilitate decision making on the basis of strong historic and forecast of Global Leukemia Therapeutic Market data.
Assess your competitor’s refining portfolio and its evolution.
Original Source of this content: https://www.sdki.jp/reports/leukemia-therapeutics-market/105927
For more information, Please contact us now:
Shibuya Data Count
Email: [email protected]
Tel: + 81 3 45720790
0 notes
Text
Car T Cell Therapy Market Share Top Trends, Business Opportunity, And Growth Strategy
The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market. The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
Request for a sample of this research Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Read More : https://www.medgadget.com/2020/02/car-t-cell-therapy-market-worth-8-92-billion-by-2026-cagr-34-5-polaris-market-research.html
0 notes
Text
CAR-T Cell Therapy Market Projected to Witness Vigorous Expansion by 2028
Global CAR-T Cell Therapy Market: Overview
The global CAR-T cell therapy market is set to chart stellar growth owing to an impressive CAGR (Compound Annual Growth Rate) between 2018 and 2028. Multiple factors driving growth in the market, and thus contributing to generation of a plethora of growth opportunities, include increase in incidence of cancer and rising investment in the field of immune oncology.
Thus, it does not come as a surprise that research is being carried out at an intense level and funding is seeing an inflow from both government and pharmaceutical players. As per WHO, it can be prevented by managing lifestyle such as smoking habits and few other parameters such as exposure to gasoline, radiation, etc. It is noteworthy here that prevention can happen only to a limited extent.
Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6173
Global CAR-T Cell Therapy Market: Notable Developments
Certain developments happening in the market place are transforming the landscape. Some of these are outlined below.
In 2017, U.S. FDA approved Tisagenlecleucel (Kymriah), CAR-T cell therapy which is historic in its right. It is used for treating ALL (Acute Lymphoblastic Leukemia) in young adults and children. This happened in August and in October of the year, Yescarta for treating refractory or relapsed diffuse large B-cell lymphomas.
In 2018, the same treatment – Kymriah – was approved for another indication. It is diffuse large B-cell Lymphoma. The same year, both treatments were approved in Europe.
The global CAR-T Cell Therapy market is consolidated and highly competitive. Key names in the global CAR-T Cell Therapy market Gilead Sciences, Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.
Global CAR T – Cell Therapy Market: ��Key trends and driver
The global CAR-T Cell Therapy market is on an upward growth curve owing to various trends and drivers. Some of the prominent ones are outlined below
Number of cases of cancer is going up, leading to a need for better therapies. And, this endeavour for reliable and effective approach is set to drive growth in global CAR-T cell therapy market. It might be pertinent to point out here that the number of patients reporting failure to certain therapies is also leading the global CAR-T cell therapy market onto a higher growth trajectory.
As a larger number of population is suffering from cancer, governments as well as pharmaceutical players are scurrying to improve outcomes, thereby, grabbing a large chunk of global CAR-T cell therapy market. And. Thus, it surprises no one that investments are pouring in to support research and development in a massive way.
To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6173
Global CAR-T Cell Therapy Market: Regional Analysis
Europe and Asia Pacific will hold a substantial share of the global CAR-T Cell Therapy Market owing to increasing cases of leukemia. North America and Europe will also see growth owing to a large patient pool, better healthcare infrastructure and good levels of awareness. Besides, research and development programs are increasing like that for Kymriah, mentioned above.. And, approvals are also contributing positively to the growth of the global CAR-T cells market. This awareness levels are also seeing a steep upward curve in the Asia Pacific region, creating lucrative opportunities for players operating in the global CAR-T Cell Therapy market.
The market is segmented as presented below:
Target Antigen
CD19
CD20
MESO
HER2
EGFRV III
Application
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma
Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6173
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
0 notes
Text
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Recent Study Including Growth Factors estimated value of $3609.37 million by 2026: Applications, Regional Analysis, Key Players and Forecasts to 2026
Definition:
Acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics are the collection of drugs and therapeutic systems available in the market for its treatment. In this cancer, the blood and bone marrow are affected with cancerous cells which result in compromise of integrity of white blood cells. It is most common in pediatric patients as it occurs when the bone marrow cell consists of errors in its DNA, this generally occurs while the bone marrow is under development.
Analysis of Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is expected to rise to an estimated value of USD 3609.37 million by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the growing levels of preference for adopting targeted therapy systems as well as increasing prevalence of bone marrow biopsies carried out.
Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Market Drivers
· Increasing prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) is expected to augment growth in the market
· Surge in the approvals of products for the treatment of this disorder is expected to drive the growth of the market
· Increasing initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease is also expected to foster growth of the market
· Advancements in technologies for treatment of disorders that have been caused by rising investments undertaken by the manufacturers is also expected to drive the growth of the market
Market Restraints
· High levels of expiration of patents associated with the drugs already in the market is expected to restrain the growth of the market
· Concerns regarding the reactions associated with the treatment options is also expected to restrict the growth of the market
· Large costs associated with the therapeutics is also expected to restrict the market growth
· Complications in the approval of drugs and therapeutic systems for treatment of this disease is expected to restrain the growth of the market
Leading Key players profiled in this report are:
Few of the major competitors currently working in the global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market are Amgen Inc.; Bristol-Myers Squibb Company; Erytech Pharma; Novartis AG; Pfizer Inc.; Rare Disease Therapeutics, Inc.; Sanofi; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Genmab A/S; Baxter; Gilead Sciences, Inc.; CELGENE CORPORATION; Eisai Co., Ltd.; SymBio Pharmaceuticals Limited; Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and medac Pharma among others
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Segmentation:
By Age Group
· Pediatrics
· Adults
By Diagnosis
· Biopsy & Bone Marrow Aspiration
· Complete Blood Count (CBC) & Differential
· Presence of Philadelphia Chromosome
· Spinal Tap (Lumbar Puncture) & Cerebrospinal Fluid (CSF) Analysis
· Immunophenotyping/Phenotyping by Flow Cytometry
· Polymerase Chain Reaction (PCR)
By Drug Type
· Existing Drugs
§ Hyper-CVAD Regimen
§ Linker Regimen
§ Nucleoside Metabolic Inhibitors
o Clolar
o Nelarabine
§ CALG 8811 Regimen
§ Oncaspar
§ Pipeline DrugsGraspa
§ Marqibo
§ Inotuzumab Ozogamicin
By Therapy
§ Targeted Drugs & Immunotherapy
§ Chemotherapy
§ Radiation Therapy
§ Stem Cell Transplantation
By Cell Type
· Philadelphia Chromosome
§ Positive (Ph+)
§ Negative (Ph-)
· Precursor B-Cell ALL
· T-Cell ALL
By Route of Administration
· Oral
· Parenteral
By Geography
· North America
· South America
· Europe
· Asia-Pacific
Company Share Analysis:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
The Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.
Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.
Access Full Report :- https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.
Contact:
Data Bridge Market Research
+1-888-387-2818
Find More Reports Related To This Category
Global Activity Tracking Fitness App Market
Global Trash Bags Market
#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market overview#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market applications
0 notes
Text
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Recent Study Including Growth Factors estimated value of $3609.37 million by 2026: Applications, Regional Analysis, Key Players and Forecasts to 2026
Definition:
Acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics are the collection of drugs and therapeutic systems available in the market for its treatment. In this cancer, the blood and bone marrow are affected with cancerous cells which result in compromise of integrity of white blood cells. It is most common in pediatric patients as it occurs when the bone marrow cell consists of errors in its DNA, this generally occurs while the bone marrow is under development.
Analysis of Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is expected to rise to an estimated value of USD 3609.37 million by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the growing levels of preference for adopting targeted therapy systems as well as increasing prevalence of bone marrow biopsies carried out.
Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Market Drivers
· Increasing prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) is expected to augment growth in the market
· Surge in the approvals of products for the treatment of this disorder is expected to drive the growth of the market
· Increasing initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease is also expected to foster growth of the market
· Advancements in technologies for treatment of disorders that have been caused by rising investments undertaken by the manufacturers is also expected to drive the growth of the market
Market Restraints
· High levels of expiration of patents associated with the drugs already in the market is expected to restrain the growth of the market
· Concerns regarding the reactions associated with the treatment options is also expected to restrict the growth of the market
· Large costs associated with the therapeutics is also expected to restrict the market growth
· Complications in the approval of drugs and therapeutic systems for treatment of this disease is expected to restrain the growth of the market
Leading Key players profiled in this report are:
Few of the major competitors currently working in the global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market are Amgen Inc.; Bristol-Myers Squibb Company; Erytech Pharma; Novartis AG; Pfizer Inc.; Rare Disease Therapeutics, Inc.; Sanofi; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Genmab A/S; Baxter; Gilead Sciences, Inc.; CELGENE CORPORATION; Eisai Co., Ltd.; SymBio Pharmaceuticals Limited; Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and medac Pharma among others
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Segmentation:
By Age Group
· Pediatrics
· Adults
By Diagnosis
· Biopsy & Bone Marrow Aspiration
· Complete Blood Count (CBC) & Differential
· Presence of Philadelphia Chromosome
· Spinal Tap (Lumbar Puncture) & Cerebrospinal Fluid (CSF) Analysis
· Immunophenotyping/Phenotyping by Flow Cytometry
· Polymerase Chain Reaction (PCR)
By Drug Type
· Existing Drugs
§ Hyper-CVAD Regimen
§ Linker Regimen
§ Nucleoside Metabolic Inhibitors
o Clolar
o Nelarabine
§ CALG 8811 Regimen
§ Oncaspar
§ Pipeline DrugsGraspa
§ Marqibo
§ Inotuzumab Ozogamicin
By Therapy
§ Targeted Drugs & Immunotherapy
§ Chemotherapy
§ Radiation Therapy
§ Stem Cell Transplantation
By Cell Type
· Philadelphia Chromosome
§ Positive (Ph+)
§ Negative (Ph-)
· Precursor B-Cell ALL
· T-Cell ALL
By Route of Administration
· Oral
· Parenteral
By Geography
· North America
· South America
· Europe
· Asia-Pacific
Company Share Analysis:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
The Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.
Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.
Access Full Report :- https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.
Contact:
Data Bridge Market Research
+1-888-387-2818
Find More Reports Related To This Category
Global Activity Tracking Fitness App Market
Global Trash Bags Market
#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market trends#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market application#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market overview
0 notes
Text
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Recent Study Including Growth Factors estimated value of $3609.37 million by 2026: Applications, Regional Analysis, Key Players and Forecasts to 2026
Definition:
Acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics are the collection of drugs and therapeutic systems available in the market for its treatment. In this cancer, the blood and bone marrow are affected with cancerous cells which result in compromise of integrity of white blood cells. It is most common in pediatric patients as it occurs when the bone marrow cell consists of errors in its DNA, this generally occurs while the bone marrow is under development.
Analysis of Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is expected to rise to an estimated value of USD 3609.37 million by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the growing levels of preference for adopting targeted therapy systems as well as increasing prevalence of bone marrow biopsies carried out.
Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Market Drivers
· Increasing prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) is expected to augment growth in the market
· Surge in the approvals of products for the treatment of this disorder is expected to drive the growth of the market
· Increasing initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease is also expected to foster growth of the market
· Advancements in technologies for treatment of disorders that have been caused by rising investments undertaken by the manufacturers is also expected to drive the growth of the market
Market Restraints
· High levels of expiration of patents associated with the drugs already in the market is expected to restrain the growth of the market
· Concerns regarding the reactions associated with the treatment options is also expected to restrict the growth of the market
· Large costs associated with the therapeutics is also expected to restrict the market growth
· Complications in the approval of drugs and therapeutic systems for treatment of this disease is expected to restrain the growth of the market
Leading Key players profiled in this report are:
Few of the major competitors currently working in the global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market are Amgen Inc.; Bristol-Myers Squibb Company; Erytech Pharma; Novartis AG; Pfizer Inc.; Rare Disease Therapeutics, Inc.; Sanofi; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Genmab A/S; Baxter; Gilead Sciences, Inc.; CELGENE CORPORATION; Eisai Co., Ltd.; SymBio Pharmaceuticals Limited; Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and medac Pharma among others
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Segmentation:
By Age Group
· Pediatrics
· Adults
By Diagnosis
· Biopsy & Bone Marrow Aspiration
· Complete Blood Count (CBC) & Differential
· Presence of Philadelphia Chromosome
· Spinal Tap (Lumbar Puncture) & Cerebrospinal Fluid (CSF) Analysis
· Immunophenotyping/Phenotyping by Flow Cytometry
· Polymerase Chain Reaction (PCR)
By Drug Type
· Existing Drugs
§ Hyper-CVAD Regimen
§ Linker Regimen
§ Nucleoside Metabolic Inhibitors
o Clolar
o Nelarabine
§ CALG 8811 Regimen
§ Oncaspar
§ Pipeline DrugsGraspa
§ Marqibo
§ Inotuzumab Ozogamicin
By Therapy
§ Targeted Drugs & Immunotherapy
§ Chemotherapy
§ Radiation Therapy
§ Stem Cell Transplantation
By Cell Type
· Philadelphia Chromosome
§ Positive (Ph+)
§ Negative (Ph-)
· Precursor B-Cell ALL
· T-Cell ALL
By Route of Administration
· Oral
· Parenteral
By Geography
· North America
· South America
· Europe
· Asia-Pacific
Company Share Analysis:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
The Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.
Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.
Access Full Report :- https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.
Contact:
Data Bridge Market Research
+1-888-387-2818
Find More Reports Related To This Category
Global Activity Tracking Fitness App Market
Global Trash Bags Market
#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market trends#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market overview#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market applications
0 notes
Link
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
Request for sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region
CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 – 2026)
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)
CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 – 2026)
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 – 2026)
U.S.
Europe
Japan
Rest of the World
Request for Discount on This Report @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world.
Contact us
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
Web: www.polarismarketresearch.com
0 notes
Text
CAR-T Cell Therapy Market Size, Competitive Landscape, Regional Outlook and Driving Factors Analysis 2026
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market
Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region
CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 – 2026)
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)
CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 – 2026)
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 – 2026)
U.S.
Europe
Japan
Rest of the World
Purchase This Report @: https://www.polarismarketresearch.com/checkouts/3521
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: www.polarismarketresearch.com
0 notes
Text
T-cell Therapy Market - Brief Analysis by Top Key Players
Rise in Prevalence of Cancer Propelled T-cell Therapy Market
T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for application in immunotherapy. Both the first two FDA-approved CAR-T therapies target the CD19 antigen, which is found on many types of B-cell cancers. Kymriah is approved to treat relapsed/refractory B-cell precursor acute lymphoblastic leukemia and Yescarta is approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Report Overview @ https://www.transparencymarketresearch.com/t-cell-therapy-market.html
Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries.
Planning To Lay Down Future Strategy? Request Brochure Of T-cell Therapy Market
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75857
Key Drivers and Restraints of Global T-cell Therapy Market
Increase in investment in adoptive T-cell transfer approaches of disease treatment drives the market. Furthermore, technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors fuel the revenue generation. The approvals and clinical success of Kymriah and Yescarta opened new and encouraging avenues for developers of cellular immunotherapies.
High prices of therapies are likely to limit the market growth in the near future. The CAR T therapy costs range between US$ 373,000 and US$ 475,000 per infusion. The reimbursement gap remains unsustainable and is a huge impediment to patient access. In the U.S., CMS recently raised reimbursement of the total cost of CAR T-cell therapies from 50% to 65%, effective from 2020.
CAR T-cell Therapy Estimated to Dominate Global T-cell Therapy Market
Based on type, the global T-cell therapy market can be divided into: CAR T-cell Therapy, T-cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based
The CAR T-cell therapy segment dominated the global T-cell therapy market in terms of revenue generation in 2018 and is expected to lead the position during the forecast period. Large number of research institutions and companies are doing clinical studies with different CAR-T products that often target the same condition.
In 2018, Kymriah, which is a T-cell therapy for the treatment of acute lymphoblastic leukemia, was manufactured for more than 300 patients intended to be used across 11 countries and 35 certified treatment centers. On the other hand, by June 2018, around 61 cancer centers were authorized for Yescarta administration to patients, which is the first CAR T therapy for adults living with certain types of non-Hodgkin lymphoma. Rise in number of research & development activities boosts the market growth.
To Obtain All-Inclusive Information On Forecast Analysis Of T-cell Therapy Market , Request A Discount
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75857
Solid Tumors Segment to Witness Highest Growth
Based on indication, the global T-cell therapy market can be divided into: Hematologic Malignancies and Solid Tumors. The hematologic malignancies segment is sub-segmented into lymphoma, leukemia, and myeloma. The solid tumors segment is further segmented into melanoma, brain & central nervous system, liver cancer, and others.
In terms of indication, the hematologic malignancies segment dominated the global T-cell therapy market in 2018. CAR T-cell therapy has efficiently proven its effectiveness for hematologic malignancies, especially diffuse B-cell lymphoma (DBCL). Over 25,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed annually in the U.S., representing an incidence rate of 6.9 per 100,000.
However, solid tumors offer tenfold greater opportunity than hematological cancers with possibly 1.3 million cancer patients annually. Effective and affordable CAR-T for solid tumors treatment offers benefits to patients and substantial investment returns to market entities.
North America to Dominate Global T-cell Therapy Market
In terms of region, the global T-cell therapy market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
In terms of revenue, North America dominated the T-Cell therapy market in 2018, followed by Europe, due to high number of sponsors from the U.S. for clinical trials, large number of research institute presence, and the U.S. FDA approval of CAR T-cell therapeutics in the U.S. and Canada. In August 2017, the first chimeric antigen receptor T-cell (CAR-T cell) therapy was approved for the market in the U.S. for targeted cancer immunotherapy, and CAR-T cell therapy developers have recently gained entry into the market in Europe as well.
Asia Pacific is expected to grow at the highest CAGR during the forecast period. Rise in number of clinical trials pertaining to CAR T-cell therapies and increase in number of diseases are anticipated to boost the growth of the market in this region.
Key Manufacturers Operating in Market
The global T-cell therapy market was highly fragmented in 2018. Key manufacturers operating in the global market are:
Novartis AG
Gilead Sciences, Inc.
TCR2 Therapeutics Inc.
Sorrento Therapeutics, Inc.
Fate Therapeutics
Merck KGaA
Pfizer
Amgen
Celgene Corporation
More Trending Reports by Transparency Market Research –
ECG Devices Market –
https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html
Request For Coronavirus Infection Market Analysis –
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940
0 notes
Text
Car T Cell Therapy Market Top Trends, Business Opportunity, and Growth Strategy
The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market. The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
Request for a sample of this research Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Read More : https://www.medgadget.com/2020/02/car-t-cell-therapy-market-worth-8-92-billion-by-2026-cagr-34-5-polaris-market-research.html
0 notes
Text
Acute lymphocytic expected to reach USD 3.4 billion by 2025 : Grand view Research , Inc.
The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.
Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.
Browse full report by Grand View Research : http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
Further Key Findings From the Report Suggest:
· Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products
· Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery
· Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes
· North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region
· Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region
· Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation
· Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies
Browse more reports of this category by Grand View Research: https://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the global acute Lymphocytic/Lymphoblastic leukemia therapeutics market on the basis of therapy, type, and region:
Therapy Outlook (Revenue, USD Million; 2014 - 2025)
· Chemotherapy
o Hyper-CVAD
o CALGB 8811 regimen
o Linker regimen
o Nucleoside Metabolic Inhibitors
o Oncaspar
· Targeted therapy
· Radiation Therapy
· Stem cell transplantation
Type Outlook (Revenue, USD Million; 2014 - 2025)
· Philadelphia chromosome
· Precursor B-cell ALL
· T-cell ALL
Regional Outlook (Revenue, USD Million; 2014 - 2025)
· North America
o U.S.
o Canada
· Europe
o UK
o Germany
o France
· Asia Pacific
o Japan
o China
o India
· Latin America
o Brazil
o Mexico
· Middle East & Africa
o South Africa
View press release of this research report by Grand View Research: https://www.grandviewresearch.com/press-release/global-acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
0 notes
Text
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Recent Study Including Growth Factors estimated value of $3609.37 million by 2026: Applications, Regional Analysis, Key Players and Forecasts to 2026
Definition:
Acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics are the collection of drugs and therapeutic systems available in the market for its treatment. In this cancer, the blood and bone marrow are affected with cancerous cells which result in compromise of integrity of white blood cells. It is most common in pediatric patients as it occurs when the bone marrow cell consists of errors in its DNA, this generally occurs while the bone marrow is under development.
Analysis of Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is expected to rise to an estimated value of USD 3609.37 million by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the growing levels of preference for adopting targeted therapy systems as well as increasing prevalence of bone marrow biopsies carried out.
Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
Market Drivers
· Increasing prevalence of acute lymphocytic/lymphoblastic leukemia (ALL) is expected to augment growth in the market
· Surge in the approvals of products for the treatment of this disorder is expected to drive the growth of the market
· Increasing initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease is also expected to foster growth of the market
· Advancements in technologies for treatment of disorders that have been caused by rising investments undertaken by the manufacturers is also expected to drive the growth of the market
Market Restraints
· High levels of expiration of patents associated with the drugs already in the market is expected to restrain the growth of the market
· Concerns regarding the reactions associated with the treatment options is also expected to restrict the growth of the market
· Large costs associated with the therapeutics is also expected to restrict the market growth
· Complications in the approval of drugs and therapeutic systems for treatment of this disease is expected to restrain the growth of the market
Leading Key players profiled in this report are:
Few of the major competitors currently working in the global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market are Amgen Inc.; Bristol-Myers Squibb Company; Erytech Pharma; Novartis AG; Pfizer Inc.; Rare Disease Therapeutics, Inc.; Sanofi; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Genmab A/S; Baxter; Gilead Sciences, Inc.; CELGENE CORPORATION; Eisai Co., Ltd.; SymBio Pharmaceuticals Limited; Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and medac Pharma among others
Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Segmentation:
By Age Group
· Pediatrics
· Adults
By Diagnosis
· Biopsy & Bone Marrow Aspiration
· Complete Blood Count (CBC) & Differential
· Presence of Philadelphia Chromosome
· Spinal Tap (Lumbar Puncture) & Cerebrospinal Fluid (CSF) Analysis
· Immunophenotyping/Phenotyping by Flow Cytometry
· Polymerase Chain Reaction (PCR)
By Drug Type
· Existing Drugs
§ Hyper-CVAD Regimen
§ Linker Regimen
§ Nucleoside Metabolic Inhibitors
o Clolar
o Nelarabine
§ CALG 8811 Regimen
§ Oncaspar
§ Pipeline DrugsGraspa
§ Marqibo
§ Inotuzumab Ozogamicin
By Therapy
§ Targeted Drugs & Immunotherapy
§ Chemotherapy
§ Radiation Therapy
§ Stem Cell Transplantation
By Cell Type
· Philadelphia Chromosome
§ Positive (Ph+)
§ Negative (Ph-)
· Precursor B-Cell ALL
· T-Cell ALL
By Route of Administration
· Oral
· Parenteral
By Geography
· North America
· South America
· Europe
· Asia-Pacific
Company Share Analysis:
Global acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
The Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.
Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.
Access Full Report :- https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.
Contact:
Data Bridge Market Research
+1-888-387-2818
Find More Reports Related To This Category
Global Activity Tracking Fitness App Market
Global Trash Bags Market
#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market trends#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market applications#Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market over
0 notes
Text
Lymphoblastic Leukemia Therapeutics Market Report Covers Revenue Forecast, Company Share, Competitive Landscape, Growth Factors And Trends 2014-2025
Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.
Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.
Full Research Report on Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis:
http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
Further Key Findings From the Report Suggest:
Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products
Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery
Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes
North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region
Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region
Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation
Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies
View more reports of this category by Grand View Research at:
http://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market on the basis of therapy, type, and region:
Therapy Outlook (Revenue, USD Million; 2014 - 2025)
Hyper-CVAD
CALGB 8811 regimen
Linker regimen
Nucleoside Metabolic Inhibitors
Oncaspar
Type Outlook (Revenue, USD Million; 2014 - 2025)
Philadelphia chromosome
Precursor B-cell ALL
T-cell ALL
Regional Outlook (Revenue, USD Million; 2014 - 2025)
U.S.
Canada
UK
Germany
France
Japan
China
India
Brazil
Mexico
South Africa
View press release of this research report by Grand View Research:
http://www.grandviewresearch.com/press-release/global-acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
0 notes
Text
Car t cell therapy Market Company Profiles, Trends by Types and Application, Operating Business Segments 2028
The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market. The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
Request for a sample of this research Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Read More : https://www.medgadget.com/2020/02/car-t-cell-therapy-market-worth-8-92-billion-by-2026-cagr-34-5-polaris-market-research.html
0 notes
Last Seen Blogs
pigeon-m
Welcome B)
pigeon-m
Welcome B)
ticklishsun
Ticklish_Sun
resuscitating-art
Resus art illustrations and stories
itsasugarcoatedsecret
Shh, it's story time!